Business
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on investigator-initiated exploratory studies and institutional collaborationsContinued progress toward IND-enabling activities for DNase I programEnded the year with $7.9 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025. Recent HighlightsExpanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and highlighting the therapeutic potential of Deoxyribonuclease (DNase) -based interventions;Progressed investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms, including:Ongoing pancreatic ductal adenocarcinoma (PDAC) study;Proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy;Advanced clinical manufacturing activities for DNase I toward Investigational New Drug (IND) application;Current focus on mechanism-of-action and translational research studies supported by encouraging CAR-T proof-of-concept studies with Scripps Research; andPursuing strategic alternatives to maximize shareholder value.\"During 2025, we continued to advance our DNase-based technology toward Phase 1 clinical development while making steady progress across scientific, operational and strategic fronts,\" said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. \"We strengthened the evidence linking NETs to cancer progression and the therapeutic promise of DNase-based strategies, advanced multiple investigator-initiated studies and progressed toward IND-enabling activities. We believe these efforts position the Company well as we move through 2026, while remaining disciplined in our use of capital and focused on creating long-term shareholder value.\"Xenetic continues to advance its DNase-based technology toward Phase 1 clinical development for the treatment of pancre...